- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Canada OKs Bellafill wrinkle filler
Health Canada has approved the use of the injectable aesthetic filler Bellafill, the San Diego Union-Tribune reports.
Ottawa, Ontario - Health Canada has approved the use of the injectable aesthetic filler Bellafill, the San Diego Union-Tribune reports.
Bellafill, manufactured by Suneva Medical, based in San Diego, is known as Artefill in the United States. The Food and Drug Administration approved Artefill, a nonresorbable, longer-lasting wrinkle treatment, in 2006.
Bellafill is composed of bovine collagen, polymethylmethacrylate beads, and a small amount of the anesthetic lidocaine.
The Union-Tribune quotes Suneva Chairman and CEO Nicholas Teti as saying, “We are currently evaluating our options for a Canadian launch. In addition, we have established international partnership agreements in several countries around the world and expect a number of international product launches later this year.”
Suneva was created when Stamford, Conn., venture capital firm Cowen Healthcare Royalty Partners acquired Artefill in 2009 after its creator, Artes Medical, filed for bankruptcy.
